{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:56:32Z","timestamp":1790603792243,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002141","name":"UKHSA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jinf.2026.106819","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:27:07Z","timestamp":1784356027000},"page":"106819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serological outcomes of SARS-CoV-2 infection by vaccination status and variant in England"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5634-7073","authenticated-orcid":false,"given":"Catherine","family":"Quinot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7905-862X","authenticated-orcid":false,"given":"Rachel","family":"Lunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freja","family":"Kirsebom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5833-1863","authenticated-orcid":false,"given":"Heather","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Skarnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Letley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Haskins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Angel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skye","family":"Firminger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Ratcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Sherridan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelina","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lola","family":"Akindele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6658-3542","authenticated-orcid":false,"given":"Samreen","family":"Ijaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Zambon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1568-683X","authenticated-orcid":false,"given":"Kevin","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie Lopez","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2026.106819_bib1","unstructured":"Agency UHS. Guidance COVID-19: the green book, chapter 14a 2023 [Available from: https:\/\/www.gov.uk\/government\/publications\/covid-19-the-green-book-chapter-14a."},{"key":"10.1016\/j.jinf.2026.106819_bib2","unstructured":"GOV.UK. Investigation of SARS-CoV-2 variants: technical briefings [Available from: https:\/\/www.gov.uk\/government\/publications\/investigation-of-sars-cov-2-variants-technical-briefings."},{"issue":"1","key":"10.1016\/j.jinf.2026.106819_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1473-3099(21)00475-8","article-title":"Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study","volume":"22","author":"Twohig","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"10332","key":"10.1016\/j.jinf.2026.106819_bib4","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(22)00462-7","article-title":"Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study","volume":"399","author":"Nyberg","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2026.106819_bib5","unstructured":"GOV.UK. UK COVID-19 vaccines delivery plan [Available from: https:\/\/www.gov.uk\/government\/publications\/uk-covid-19-vaccines-delivery-plan\/uk-covid-19-vaccines-delivery-plan."},{"issue":"6","key":"10.1016\/j.jinf.2026.106819_bib6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.it.2020.04.008","article-title":"Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses: (Trends in Immunology 41, 355-359; 2020)","volume":"41","author":"Jiang","year":"2020","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jinf.2026.106819_bib7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijid.2022.07.053","article-title":"Nucleocapsid and spike antibody responses following virologically confirmed SARS-CoV-2 infection: an observational analysis in the Virus Watch community cohort","volume":"123","author":"Navaratnam","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2026.106819_bib8","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2666-7568(21)00282-8","article-title":"Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England","volume":"3","author":"Krutikov","year":"2022","journal-title":"Lancet Healthy Longev"},{"issue":"7","key":"10.1016\/j.jinf.2026.106819_bib9","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1016\/S2666-7568(22)00118-0","article-title":"Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study","volume":"3","author":"Tut","year":"2022","journal-title":"Lancet Healthy Longev"},{"issue":"4","key":"10.1016\/j.jinf.2026.106819_bib10","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3201\/eid2704.204554","article-title":"Persistence of SARS-CoV-2 N-Antibody Response in Healthcare Workers, London, UK","volume":"27","author":"Shrotri","year":"2021","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2026.106819_bib11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jinf.2021.04.028","article-title":"Seroprevalence of SARS-CoV-2 antibodies in university students: Cross-sectional study, December 2020, England","volume":"83","author":"Vusirikala","year":"2021","journal-title":"J Infect"},{"issue":"7","key":"10.1016\/j.jinf.2026.106819_bib12","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.tim.2021.03.016","article-title":"Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses","volume":"29","author":"Siggins","year":"2021","journal-title":"Trends Microbiol"},{"issue":"1","key":"10.1016\/j.jinf.2026.106819_bib13","article-title":"Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients","volume":"11","author":"Chansaenroj","year":"2021","journal-title":"Sci Rep-Uk"},{"issue":"4","key":"10.1016\/j.jinf.2026.106819_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0267102","article-title":"Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients","volume":"17","author":"Chansaenroj","year":"2022","journal-title":"Plos One"},{"issue":"3","key":"10.1016\/j.jinf.2026.106819_bib15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/v13030422","article-title":"Antibody response to the BNT162b2 mRNA COVID-19 vaccine in subjects with prior SARS-CoV-2 infection","volume":"13","author":"Gobbi","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.jinf.2026.106819_bib16","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1038\/s41467-022-32265-5","article-title":"SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort","volume":"13","author":"Aldridge","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jinf.2026.106819_bib17","unstructured":"GOV.UK. SIREN study [Available from: https:\/\/www.gov.uk\/guidance\/siren-study."},{"key":"10.1016\/j.jinf.2026.106819_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmedinf.2022.104974","article-title":"Monitoring the COVID-19 immunisation programme through a national immunisation Management system - England's experience","volume":"170","author":"Tessier","year":"2023","journal-title":"Int J Med Inform"},{"key":"10.1016\/j.jinf.2026.106819_bib19","unstructured":"GOV.UK. Guidance COVID-19 testing data: methodology note 2020 [Available from: https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-testing-data-methodology\/covid-19-testing-data-methodology-note."},{"issue":"1","key":"10.1016\/j.jinf.2026.106819_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00786-21","article-title":"SARS antibody testing in children: development of oral fluid assays for IgG measurements","volume":"10","author":"Hoschler","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"2","key":"10.1016\/j.jinf.2026.106819_bib21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jinf.2022.05.033","article-title":"Mapping of SARS-CoV-2 IgM and IgG in gingival crevicular fluid: Antibody dynamics and linkage to severity of COVID-19 in hospital inpatients","volume":"85","author":"Ijaz","year":"2022","journal-title":"J Infect"},{"issue":"32","key":"10.1016\/j.jinf.2026.106819_bib22","article-title":"Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020","volume":"25","author":"Singanayagam","year":"2020"},{"key":"10.1016\/j.jinf.2026.106819_bib23","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/jalm\/jfad042","article-title":"Association between SARS-CoV-2 Symptoms, Ct Values, and Serological response in vaccinated and Unvaccinated Healthcare Personnel","author":"Farnsworth","year":"2023","journal-title":"J Appl Lab Med"},{"key":"10.1016\/j.jinf.2026.106819_bib24","doi-asserted-by":"crossref","unstructured":"Whitaker H.J., Gower C., Otter A.D., Simmons R., Kirsebom F., Letley L., et al. Nucleocapsid antibody positivity as a marker of past SARS-CoV-2 infection in population serosurveillance studies: impact of variant, vaccination, and choice of assay cut-off. 2021:2021.10.25.21264964.","DOI":"10.1101\/2021.10.25.21264964"},{"issue":"9","key":"10.1016\/j.jinf.2026.106819_bib25","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.7326\/M22-1300","article-title":"Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial","volume":"175","author":"Follmann","year":"2022","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.jinf.2026.106819_bib26","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jinf.2021.12.044","article-title":"Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups","volume":"84","author":"Whitaker","year":"2022","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.jinf.2026.106819_bib27","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1038\/s41467-022-33550-z","article-title":"Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study","volume":"13","author":"Shrotri","year":"2022","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.jinf.2026.106819_bib28","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1093\/cid\/ciab004","article-title":"The duration, dynamics, and determinants of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) antibody responses in individual healthcare workers","volume":"73","author":"Lumley","year":"2021","journal-title":"Clin Infect Dis Publ Infect Dis Soc Am"},{"issue":"12","key":"10.1016\/j.jinf.2026.106819_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244126","article-title":"Antibody response to SARS-CoV-2 infection in humans: a systematic review","volume":"15","author":"Post","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jinf.2026.106819_bib30","doi-asserted-by":"crossref","unstructured":"Clifford S., Waight P., Hackman J., Hu\u00e9 S., Gower C.M., Kirsebom F.C., et al. Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission: a prospective cohort study in England. 2021:2021.11.24.21266401.","DOI":"10.1101\/2021.11.24.21266401"},{"issue":"5","key":"10.1016\/j.jinf.2026.106819_bib31","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41591-022-01721-6","article-title":"Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines","volume":"28","author":"Wei","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jinf.2026.106819_bib32","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1038\/s41467-023-38275-1","article-title":"Protection against SARS-CoV-2 Omicron BA.4\/5 variant following booster vaccination or breakthrough infection in the UK","volume":"14","author":"Wei","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.jinf.2026.106819_bib33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"issue":"7851","key":"10.1016\/j.jinf.2026.106819_bib34","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of antibody immunity to SARS-CoV-2","volume":"591","author":"Gaebler","year":"2021","journal-title":"Nature"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326001453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326001453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:10:56Z","timestamp":1790601056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445326001453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0163445326001453"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106819","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serological outcomes of SARS-CoV-2 infection by vaccination status and variant in England","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106819","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Ltd on behalf of British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106819"}}